A comparative study of the levonorgestrel-releasing intrauterine system Mirena® versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development

Mirena® is a levonorgestrel-releasing intrauterine system (LNG-IUS) that provides highly effective and long-acting progestogen-only contraception. The objective of this study was to analyze the possible effects of using LNG-20 μg IUS on breast-feeding performance, infant growth and infant developmen...

Full description

Saved in:

Bibliographic Details
Published in:	Contraception (Stoneham) Vol. 72; no. 5; pp. 346 - 351
Main Authors:	Shaamash, Ayman H., Sayed, Gamal H., Hussien, Mostafa M., Shaaban, Mamdouh M.
Format:	Journal Article
Language:	English
Published:	New York, NY Elsevier Inc 01-11-2005 Elsevier Science
Subjects:	Adult Biological and medical sciences Birth control Breast Feeding - statistics & numerical data Breast-feeding Child Development - drug effects Child Development - physiology Contraceptive Agents, Female - adverse effects Contraceptive Agents, Female - pharmacology Egypt Female Follow-Up Studies Genital system. Reproduction Gynecology. Andrology. Obstetrics Humans Infant Infant growth and development Intrauterine Devices, Copper - adverse effects Intrauterine Devices, Medicated - adverse effects Lactation - drug effects Levonorgestrel - adverse effects Levonorgestrel - pharmacology Levonorgestrel-releasing intrauterine system Male Medical sciences Other methods of contraception. Sterilization Pharmacology. Drug treatments Prospective Studies Egypt Infant growth and development Breast-feeding Levonorgestrel-releasing intrauterine system Human Lactation Levonorgestrel Infant Breast feeding Progestagen Active substance loaded intrauterine device Female Contraceptive Copper Somatic growth Comparative study
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Mirena® is a levonorgestrel-releasing intrauterine system (LNG-IUS) that provides highly effective and long-acting progestogen-only contraception. The objective of this study was to analyze the possible effects of using LNG-20 μg IUS on breast-feeding performance, infant growth and infant development during the first postpartum year as compared with the Copper T380A intrauterine device (Cu T380A IUD). This study is a prospective, controlled and randomized trial. The study was conducted at the Department of Obstetrics and Gynecology, Assiut University Hospital, Egypt. Three hundred twenty lactating women asking for initiation of contraception during the early postpartum stage were assigned randomly into two groups, the LNG-20 μg IUS group ( n=163) and the Cu T380A group ( n=157). The insertions were done 6–8 weeks postpartum. Each participant was followed up at three monthly intervals after insertion and until the first birthday of her baby. During these visits, the breast-feeding pattern was assessed, certain infant physical growth parameters were measured and a set of infant development tests was performed. No pregnancy occurred in both groups. There were no significant differences in the net continuation rates between the two groups (89.3 for LNG-IUS vs. 90.9 for Cu T380A). The LNG-20 μg IUS group had comparable rates of breast-feeding continuation, complete weaning, full breast-feeding and partial breast-feeding, with the Cu-IUD group. No statistically significant differences were found between groups with regard to all infant physical growth parameters and various infant development tests. The findings of the current study confirm that the use of LNG-20 μg IUS during the first postpartum year in lactating women provides highly effective and acceptable contraception and does not negatively influence breast-feeding or the growth and development of breast-fed infants.
ISSN:	0010-7824 1879-0518
DOI:	10.1016/j.contraception.2005.04.004